Literature DB >> 22118109

Randomized clinical trial to evaluate the efficacy of a 5-day ceftiofur hydrochloride intramammary treatment on nonsevere gram-negative clinical mastitis.

Y H Schukken1, G J Bennett, M J Zurakowski, H L Sharkey, B J Rauch, M J Thomas, B Ceglowski, R L Saltman, N Belomestnykh, R N Zadoks.   

Abstract

The objective of this study was to evaluate the efficacy of intramammary treatment with ceftiofur hydrochloride of nonsevere, clinical coliform mastitis. One hundred four cases on 5 farms met the enrollment criteria for the study. Escherichia coli was the most common coliform species identified in milk samples from cows with mild to moderate clinical mastitis, followed by Klebsiella spp. and Enterobacter spp. At enrollment, a milk sample from the affected quarter was taken and used for on-farm culture or submitted to the laboratory. For cows in the treatment group, treatment was initiated with ceftiofur hydrochloride via intramammary infusion at 24-h intervals for 5 d according to label standards. Cows in the control group did not receive treatment. Culture results were available on the day after enrollment and only cows with coliform mastitis continued in the treatment and untreated control groups. Bacteriological cure was defined based on 2 posttreatment milk samples. Molecular typing was used for final definition of bacteriological cure. Treatment of nonsevere clinical gram-negative mastitis with ceftiofur hydrochloride resulted in a significant increase in bacteriological cure compared with nontreated controls in animals infected with E. coli or Klebsiella spp. Treated animals clinically improved significantly more compared with control cows. No significant differences were observed between treated and control animals in milk production or linear score before or after clinical mastitis. Treated animals left the study less frequently compared with control animals.
Copyright © 2011 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118109     DOI: 10.3168/jds.2011-4290

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  14 in total

1.  Klebsiella-induced infections in domestic species: a case-series study in 697 animals (1997-2019).

Authors:  Márcio Garcia Ribeiro; Amanda Bonalume Cordeiro de Morais; Ana Carolina Alves; Carmen Alicia Daza Bolaños; Carolina Lechinski de Paula; Fábio Vinicius Ramos Portilho; Geraldo de Nardi Júnior; Gustavo Henrique Batista Lara; Lorrayne de Souza Araújo Martins; Lucieny Sierra Moraes; Rafaela Mastrangelo Risseti; Simony Trevizan Guerra; Thaís Spessotto Bello; Amanda Keller Siqueira; Amanda Bezerra Bertolini; Carolina Aparecida Rodrigues; Natália Rodrigues Paschoal; Beatriz Oliveira de Almeida; Fernando José Paganini Listoni; Luísa Fernanda García Sánchez; Antonio Carlos Paes
Journal:  Braz J Microbiol       Date:  2022-01-11       Impact factor: 2.476

2.  Predictive value of prepartum serum metabolites for incidence of clinical and subclinical mastitis in grazing primiparous Holstein cows.

Authors:  Elizabeth Schwegler; Augusto Schneider; Paula Montagner; Diego Andres Velasco Acosta; Luiz Francisco Machado Pfeifer; Eduardo Schmitt; Viviane Rohrig Rabassa; Francisco Augusto Burkert Del Pino; Helenice de Lima Gonzalez; Cláudio Dias Timm; Marcio Nunes Corrêa
Journal:  Trop Anim Health Prod       Date:  2013-03-23       Impact factor: 1.559

3.  Impact of intramammary treatment on gene expression profiles in bovine Escherichia coli mastitis.

Authors:  Anja Sipka; Suzanne Klaessig; Gerald E Duhamel; Jantijn Swinkels; Pascal Rainard; Ynte Schukken
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240

4.  Klebsiella species associated with bovine mastitis in Newfoundland.

Authors:  Milka P Podder; Laura Rogers; Peter K Daley; Greg P Keefe; Hugh G Whitney; Kapil Tahlan
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

5.  Evaluation of an On-Farm Culture System (Accumast) for Fast Identification of Milk Pathogens Associated with Clinical Mastitis in Dairy Cows.

Authors:  Erika Korzune Ganda; Rafael Sisconeto Bisinotto; Dean Harrison Decter; Rodrigo Carvalho Bicalho
Journal:  PLoS One       Date:  2016-05-13       Impact factor: 3.240

6.  Longitudinal metagenomic profiling of bovine milk to assess the impact of intramammary treatment using a third-generation cephalosporin.

Authors:  Erika K Ganda; Rafael S Bisinotto; Svetlana F Lima; Kristina Kronauer; Dean H Decter; Georgios Oikonomou; Ynte H Schukken; Rodrigo C Bicalho
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

7.  Elimination kinetics of ceftiofur hydrochloride in milk after an 8-day extended intramammary administration in healthy and infected cows.

Authors:  Rongwei Han; Songli Li; Jun Wang; Zhongna Yu; Jiaqi Wang; Nan Zheng
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

8.  Normal milk microbiome is reestablished following experimental infection with Escherichia coli independent of intramammary antibiotic treatment with a third-generation cephalosporin in bovines.

Authors:  Erika K Ganda; Natalia Gaeta; Anja Sipka; Brianna Pomeroy; Georgios Oikonomou; Ynte H Schukken; Rodrigo C Bicalho
Journal:  Microbiome       Date:  2017-07-12       Impact factor: 14.650

9.  Characteristics of Escherichia coli Isolated from Bovine Mastitis Exposed to Subminimum Inhibitory Concentrations of Cefalotin or Ceftazidime.

Authors:  Gang Liu; Laidi Ding; Bo Han; Sofie Piepers; S Ali Naqvi; Herman W Barkema; Tariq Ali; Sarne De Vliegher; Siyu Xu; Jian Gao
Journal:  Biomed Res Int       Date:  2018-11-01       Impact factor: 3.411

10.  Efficacy of cefquinome and a combination of cloxacillin and ampicillin for treatment of dairy cows with Streptococcus agalactiae subclinical mastitis.

Authors:  Rodolfo Santos Rossi; Ariadne Ferreira Amarante; Simony Trevisan Guerra; Giulia Soares Latosinski; Bruna Fernanda Rossi; Vera Lucia Mores Rall; Jose Carlos de Figueiredo Pantoja
Journal:  PLoS One       Date:  2019-04-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.